Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine.

Aguirre AJ, Nowak JA, Camarda ND, Moffitt RA, Ghazani AA, Hazar-Rethinam M, Raghavan S, Kim J, Brais LK, Ragon D, Welch MW, Reilly E, McCabe D, Marini L, Anderka K, Helvie K, Oliver N, Babic A, Da Silva A, Nadres B, Van Seventer EE, Shahzade HA, St Pierre JP, Burke KP, Clancy T, Cleary JM, Doyle LA, Jajoo K, McCleary NJ, Meyerhardt JA, Murphy JE, Ng K, Patel AK, Perez K, Rosenthal MH, Rubinson DA, Ryou M, Shapiro GI, Sicinska E, Silverman SG, Nagy RJ, Lanman RB, Knoerzer D, Welsch DJ, Yurgelun MB, Fuchs CS, Garraway LA, Getz G, Hornick JL, Johnson BE, Kulke MH, Mayer RJ, Miller JW, Shyn PB, Tuveson DA, Wagle N, Yeh JJ, Hahn WC, Corcoran RB, Carter SL, Wolpin BM.

Cancer Discov. 2018 Sep;8(9):1096-1111. doi: 10.1158/2159-8290.CD-18-0275. Epub 2018 Jun 14.

2.

Tumor stroma-targeted antibody-drug conjugate triggers localized anticancer drug release.

Szot C, Saha S, Zhang XM, Zhu Z, Hilton MB, Morris K, Seaman S, Dunleavey JM, Hsu KS, Yu GJ, Morris H, Swing DA, Haines DC, Wang Y, Hwang J, Feng Y, Welsch D, DeCrescenzo G, Chaudhary A, Zudaire E, Dimitrov DS, St Croix B.

J Clin Invest. 2018 Jul 2;128(7):2927-2943. doi: 10.1172/JCI120481. Epub 2018 Jun 4.

3.

Effect of ulixertinib, a novel ERK1/2 inhibitor, on the QT/QTc interval in patients with advanced solid tumor malignancies.

Mendzelevski B, Ferber G, Janku F, Li BT, Sullivan RJ, Welsch D, Chi W, Jackson J, Weng O, Sager PT.

Cancer Chemother Pharmacol. 2018 Jun;81(6):1129-1141. doi: 10.1007/s00280-018-3564-1. Epub 2018 Mar 30.

4.

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.

Sullivan RJ, Infante JR, Janku F, Wong DJL, Sosman JA, Keedy V, Patel MR, Shapiro GI, Mier JW, Tolcher AW, Wang-Gillam A, Sznol M, Flaherty K, Buchbinder E, Carvajal RD, Varghese AM, Lacouture ME, Ribas A, Patel SP, DeCrescenzo GA, Emery CM, Groover AL, Saha S, Varterasian M, Welsch DJ, Hyman DM, Li BT.

Cancer Discov. 2018 Feb;8(2):184-195. doi: 10.1158/2159-8290.CD-17-1119. Epub 2017 Dec 15.

5.

Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib).

Germann UA, Furey BF, Markland W, Hoover RR, Aronov AM, Roix JJ, Hale M, Boucher DM, Sorrell DA, Martinez-Botella G, Fitzgibbon M, Shapiro P, Wick MJ, Samadani R, Meshaw K, Groover A, DeCrescenzo G, Namchuk M, Emery CM, Saha S, Welsch DJ.

Mol Cancer Ther. 2017 Nov;16(11):2351-2363. doi: 10.1158/1535-7163.MCT-17-0456. Epub 2017 Sep 22.

6.

Eradication of Tumors through Simultaneous Ablation of CD276/B7-H3-Positive Tumor Cells and Tumor Vasculature.

Seaman S, Zhu Z, Saha S, Zhang XM, Yang MY, Hilton MB, Morris K, Szot C, Morris H, Swing DA, Tessarollo L, Smith SW, Degrado S, Borkin D, Jain N, Scheiermann J, Feng Y, Wang Y, Li J, Welsch D, DeCrescenzo G, Chaudhary A, Zudaire E, Klarmann KD, Keller JR, Dimitrov DS, St Croix B.

Cancer Cell. 2017 Apr 10;31(4):501-515.e8. doi: 10.1016/j.ccell.2017.03.005.

7.

Evaluation of 1-(2-deoxy-2-fluoro-1-D-arabinofuranosyl)-5-iodouracil (FIAU) as an ex vivo bacterial detection agent.

Tung D, DeCrescenzo G, Welsch D, Cheung PH, Bettegowda C, Saha S.

World J Microbiol Biotechnol. 2014 Nov;30(11):3003-10. doi: 10.1007/s11274-014-1709-x. Epub 2014 Aug 2.

PMID:
25085723
8.

The CTSA Pharmaceutical Assets Portal - a public-private partnership model for drug repositioning.

Marusina K, Welsch DJ, Rose L, Brock D, Bahr N.

Drug Discov Today Ther Strateg. 2011 Winter;8(3-4):77-83.

9.

Orally active MMP-1 sparing α-tetrahydropyranyl and α-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.

Becker DP, Barta TE, Bedell LJ, Boehm TL, Bond BR, Carroll J, Carron CP, Decrescenzo GA, Easton AM, Freskos JN, Funckes-Shippy CL, Heron M, Hockerman S, Howard CP, Kiefer JR, Li MH, Mathis KJ, McDonald JJ, Mehta PP, Munie GE, Sunyer T, Swearingen CA, Villamil CI, Welsch D, Williams JM, Yu Y, Yao J.

J Med Chem. 2010 Sep 23;53(18):6653-80. doi: 10.1021/jm100669j.

PMID:
20726512
10.

Discovery of an Oral Potent Selective Inhibitor of Hematopoietic Prostaglandin D Synthase (HPGDS).

Carron CP, Trujillo JI, Olson KL, Huang W, Hamper BC, Dice T, Neal BE, Pelc MJ, Day JE, Rohrer DC, Kiefer JR, Moon JB, Schweitzer BA, Blake TD, Turner SR, Woerndle R, Case BL, Bono CP, Dilworth VM, Funckes-Shippy CL, Hood BL, Jerome GM, Kornmeier CM, Radabaugh MR, Williams ML, Davies MS, Wegner CD, Welsch DJ, Abraham WM, Warren CJ, Dowty ME, Hua F, Zutshi A, Yang JZ, Thorarensen A.

ACS Med Chem Lett. 2010 Feb 2;1(2):59-63. doi: 10.1021/ml900025z. eCollection 2010 May 13.

11.

Experimental test of a new technique to overcome spin-depolarizing resonances.

Morozov VS, Chao AW, Krisch AD, Leonova MA, Raymond RS, Sivers DW, Wong VK, Garishvili A, Gebel R, Lehrach A, Lorentz B, Maier R, Prasuhn D, Stockhorst H, Welsch D, Hinterberger F, Kondratenko AM.

Phys Rev Lett. 2009 Jun 19;102(24):244801. Epub 2009 Jun 16.

PMID:
19659013
12.

Experimental verification of predicted beam-polarization oscillations near a spin resonance.

Morozov VS, Chao AW, Krisch AD, Leonova MA, Raymond RS, Sivers DW, Wong VK, Garishvili A, Gebel R, Lehrach A, Lorentz B, Maier R, Prasuhn D, Stockhorst H, Welsch D, Hinterberger F, Ulbrich K, Schnase A, Stephenson EJ, Brantjes NP, Onderwater CJ, da Silva M.

Phys Rev Lett. 2008 Feb 8;100(5):054801. Epub 2008 Feb 5.

PMID:
18352378
13.

Discovery and development of a type II collagen neoepitope (TIINE) biomarker for matrix metalloproteinase activity: from in vitro to in vivo.

Nemirovskiy OV, Dufield DR, Sunyer T, Aggarwal P, Welsch DJ, Mathews WR.

Anal Biochem. 2007 Feb 1;361(1):93-101. Epub 2006 Nov 15. Erratum in: Anal Biochem. 2007 Nov 15;370(2):258.

PMID:
17187753
14.

Association between concentrations of urinary type II collagen neoepitope (uTIINE) and joint space narrowing in patients with knee osteoarthritis.

Hellio Le Graverand MP, Brandt KD, Mazzuca SA, Katz BP, Buck R, Lane KA, Pickering E, Nemirovskiy OV, Sunyer T, Welsch DJ.

Osteoarthritis Cartilage. 2006 Nov;14(11):1189-95. Epub 2006 Jun 6.

15.

Quantum theory of light and noise polarization in nonlinear optics.

Scheel S, Welsch DG.

Phys Rev Lett. 2006 Feb 24;96(7):073601. Epub 2006 Feb 23.

PMID:
16606088
16.

Simulation of future stream alkalinity under changing deposition and climate scenarios.

Welsch DL, Cosby BJ, Hornberger GM.

Sci Total Environ. 2006 Aug 31;367(2-3):800-10. Epub 2006 Apr 4.

PMID:
16600331
17.

The ligand-dependent interaction of mineralocorticoid receptor with coactivator and corepressor peptides suggests multiple activation mechanisms.

Hultman ML, Krasnoperova NV, Li S, Du S, Xia C, Dietz JD, Lala DS, Welsch DJ, Hu X.

Mol Endocrinol. 2005 Jun;19(6):1460-73. Epub 2005 Mar 10.

PMID:
15761029
18.

Solution structure and backbone dynamics of the catalytic domain of matrix metalloproteinase-2 complexed with a hydroxamic acid inhibitor.

Feng Y, Likos JJ, Zhu L, Woodward H, Munie G, McDonald JJ, Stevens AM, Howard CP, De Crescenzo GA, Welsch D, Shieh HS, Stallings WC.

Biochim Biophys Acta. 2002 Jul 29;1598(1-2):10-23.

PMID:
12147339
19.

Metalloproteases and inhibitors in arthritic diseases.

Martel-Pelletier J, Welsch DJ, Pelletier JP.

Best Pract Res Clin Rheumatol. 2001 Dec;15(5):805-29. Review.

PMID:
11812023
20.

Lipid remodeling in mouse liver and plasma resulting from delta6 fatty acid desaturase inhibition.

Duffin KL, Obukowicz MG, Salsgiver WJ, Welsch DJ, Shieh C, Raz A, Needleman P.

Lipids. 2001 Nov;36(11):1203-8.

PMID:
11795852
21.

CD95-induced JNK activation signals are transmitted by the death-inducing signaling complex (DISC), but not by Daxx.

Hofmann TG, Möller A, Hehner SP, Welsch D, Dröge W, Schmitz ML.

Int J Cancer. 2001 Jul 15;93(2):185-91.

22.

Enhanced quantum correlations in bound higher-order solitons

Schmidt E, Knoll L, Welsch DG, Zielonka M, Konig F, Sizmann A.

Phys Rev Lett. 2000 Oct 30;85(18):3801-4.

PMID:
11041931
23.

1H, 13C and 15N resonance assignments for a truncated and inhibited catalytic domain of matrix metalloproteinase-2.

Feng Y, Likos J, Zhu L, Woodward H, McDonald J, Stevens A, Howard S, Welsch D.

J Biomol NMR. 2000 May;17(1):85-6. No abstract available.

PMID:
10909870
24.

Novel, selective delta6 or delta5 fatty acid desaturase inhibitors as antiinflammatory agents in mice.

Obukowicz M, Welsch D, Salsgiver W, Martin-Berger C, Chinn K, Duffin K, Raz A, Needleman P.

Lipids. 1999;34 Suppl:S149. No abstract available.

PMID:
10419129
25.

Discovery of a novel series of selective MMP inhibitors: identification of the gamma-sulfone-thiols.

Freskos JN, Mischke BV, DeCrescenzo GA, Heintz R, Getman DP, Howard SC, Kishore NN, McDonald JJ, Munie GE, Rangwala S, Swearingen CA, Voliva C, Welsch DJ.

Bioorg Med Chem Lett. 1999 Apr 5;9(7):943-8.

PMID:
10230616
26.

Novel, selective delta6 or delta5 fatty acid desaturase inhibitors as antiinflammatory agents in mice.

Obukowicz MG, Welsch DJ, Salsgiver WJ, Martin-Berger CL, Chinn KS, Duffin KL, Raz A, Needleman P.

J Pharmacol Exp Ther. 1998 Oct;287(1):157-66.

PMID:
9765335
27.

Modulation of adjuvant-induced arthritis by dietary arachidonic acid in essential fatty acid-deficient rats.

Chinn KS, Welsch DJ, Salsgiver WJ, Mehta A, Raz A, Obukowicz MG.

Lipids. 1997 Sep;32(9):979-88.

PMID:
9307941
28.

Direct sampling of density matrices in field-strength bases.

Zucchetti A, Vogel W, Tasche M, Welsch D.

Phys Rev A. 1996 Aug;54(2):1678-1681. No abstract available.

PMID:
9913638
29.

Quantum-optical input-output relations for dispersive and lossy multilayer dielectric plates.

Gruner T, Welsch D.

Phys Rev A. 1996 Aug;54(2):1661-1677. No abstract available.

PMID:
9913637
30.

Quantum-state homodyne measurement with vacuum ports.

Zucchetti A, Vogel W, Welsch D.

Phys Rev A. 1996 Jul;54(1):856-862. No abstract available.

PMID:
9913542
31.

Propagation of squeezed-light pulses in dispersive and absorbing linear dielectrics.

Schmidt E, Knöll L, Welsch DG.

Phys Rev A. 1996 Jul;54(1):843-855. No abstract available.

PMID:
9913541
32.

Parametrized discrete phase-space functions.

Opatrn T, Welsch D, Buzek V V.

Phys Rev A. 1996 Jun;53(6):3822-3835. No abstract available.

PMID:
9913345
33.

Green-function approach to the radiation-field quantization for homogeneous and inhomogeneous Kramers-Kronig dielectrics.

Gruner T, Welsch D.

Phys Rev A. 1996 Mar;53(3):1818-1829. No abstract available.

PMID:
9913077
34.

Reconstruction of the quantum state of multimode light.

Kühn H, Welsch D, Vogel W.

Phys Rev A. 1995 May;51(5):4240-4249. No abstract available.

PMID:
9912100
35.

Correlation of radiation-field ground-state fluctuations in a dispersive and lossy dielectric.

Gruner T, Welsch D.

Phys Rev A. 1995 Apr;51(4):3246-3256. No abstract available.

PMID:
9911965
36.

Molecular cloning and expression of human leukotriene C4 synthase.

Welsch DJ, Creely DP, Mathis KJ, Hauser SD, Isakson PC.

Adv Prostaglandin Thromboxane Leukot Res. 1995;23:167-9. No abstract available.

PMID:
7732826
37.

Molecular cloning and expression of human leukotriene-C4 synthase.

Welsch DJ, Creely DP, Hauser SD, Mathis KJ, Krivi GG, Isakson PC.

Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):9745-9.

38.

Renaturation and purification of human tissue factor pathway inhibitor expressed in recombinant E. coli.

Gustafson ME, Junger KD, Wun TC, Foy BA, Diaz-Collier JA, Welsch DJ, Obukowicz MG, Bishop BF, Bild GS, Leimgruber RM, et al.

Protein Expr Purif. 1994 Jun;5(3):233-41.

PMID:
7950366
40.

Comparison of recombinant tissue factor pathway inhibitors expressed in human SK hepatoma, mouse C127, baby hamster kidney, and Chinese hamster ovary cells.

Wun TC, Kretzmer KK, Palmier MO, Day KC, Huang MD, Welsch DJ, Lewis C, Wolfe RA, Zobel JF, Lange GW, et al.

Thromb Haemost. 1992 Jul 6;68(1):54-9.

PMID:
1325078
41.
42.

Transient-gain-assisted noise reduction in photodetection of nonclassical light.

Kühn H, Welsch D.

Phys Rev Lett. 1991 Jul 29;67(5):580-583. No abstract available.

PMID:
10044934
43.

Nonperturbative approach to multimode photodetection.

Fleischhauer M, Welsch DG.

Phys Rev A. 1991 Jul 1;44(1):747-755. No abstract available.

PMID:
9905725
44.

Resonators in quantum optics: A first-principles approach.

Knöll L, Vogel W, Welsch D.

Phys Rev A. 1991 Jan 1;43(1):543-553. No abstract available.

PMID:
9904808
45.

Erratum: k-photon Jaynes-Cummings model with coherent atomic preparation: Squeezing and coherence

Vogel W, Welsch D.

Phys Rev A. 1990 Oct 1;42(7):4407. No abstract available.

PMID:
9904546
46.

Molecular defect (Gla+14----Lys) and its functional consequences in a hereditary factor X deficiency (factor X "Vorarlberg").

Watzke HH, Lechner K, Roberts HR, Reddy SV, Welsch DJ, Friedman P, Mahr G, Jagadeeswaran P, Monroe DM, High KA.

J Biol Chem. 1990 Jul 15;265(20):11982-9.

47.

Spectral properties of light in quantum optics.

Knöll L, Vogel W, Welsch D.

Phys Rev A. 1990 Jul 1;42(1):503-522. No abstract available.

PMID:
9903829
48.

Partial purification and characterization of bovine liver aspartyl beta-hydroxylase.

Gronke RS, Welsch DJ, VanDusen WJ, Garsky VM, Sardana MK, Stern AM, Friedman PA.

J Biol Chem. 1990 May 25;265(15):8558-65.

49.

Expression and characterization of human factor IX and factor IX-factor X chimeras in mouse C127 cells.

Lin SW, Smith KJ, Welsch D, Stafford DW.

J Biol Chem. 1990 Jan 5;265(1):144-50.

50.

k-photon Jaynes-Cummings model with coherent atomic preparation: Squeezing and coherence.

Vogel W, Welsch D.

Phys Rev A Gen Phys. 1989 Dec 15;40(12):7113-7120. No abstract available.

PMID:
9902125

Supplemental Content

Loading ...
Support Center